Drug Profile
Firategrast
Alternative Names: 683699; SB-683699; T-0047Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Tanabe Seiyaku
- Developer GSK; Tanabe Seiyaku
- Class
- Mechanism of Action Integrin alpha4beta1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Multiple sclerosis
- Discontinued Asthma; Crohn's disease; Inflammatory bowel diseases; Rheumatoid arthritis
Most Recent Events
- 31 Aug 2015 No recent reports of development identified - Phase-I for Multiple sclerosis (In volunteers) in Australia (PO, Controlled-release)
- 31 Aug 2015 No recent reports of development identified - Phase-I for Multiple sclerosis (In volunteers) in Australia (PO, Suspension)
- 31 Aug 2015 No recent reports of development identified - Phase-II for Multiple sclerosis in Canada, Oceania, USA and Europe (PO, Tablet)